<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026336</url>
  </required_header>
  <id_info>
    <org_study_id>10/122/1161</org_study_id>
    <nct_id>NCT02026336</nct_id>
  </id_info>
  <brief_title>E-nose and Inflammatory Asthma Phenotypes</brief_title>
  <official_title>Inflammatory Asthma Phenotypes Discrimination by an Electronic Nose Breath Analyzer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astrid Crespo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with persistent asthma have different inflammatory phenotypes. The electronic nose
      is a new technology capable of distinguishing volatile organic compound breath-prints in
      exhaled breath among different pulmonary diseases.

      Question of the study. Is the electronic nose breath-print analysis able to discriminate
      among different inflammatory asthma phenotypes?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Materials/patients and methods. Fifty-two consecutively enrolled patients with persistent
      asthma were included in a cross-sectional proof of concept study. Inflammatory asthma
      phenotypes were recognized by inflammatory cell counts in induced sputum. Breath-prints were
      analyzed by discriminant analysis on principal component reduction, resulting in
      cross-validated accuracy values. Receiver Operating Characteristics (ROC) was calculated.

      Legal and ethical aspects The study was conducted in accordance with the Declaration of
      Helsinki principles (18th Word Medical Assembly, 1964) and was approved by the Clinical
      Research Ethics Committee (approval number: IIBSP/10/122/1161) of our institution. The
      participants provided their written informed consent to participate in this study and
      personal identification data were anonymized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Asthma Phenotypes Discrimination by an Electronic Nose Breath Analyzer</measure>
    <time_frame>2 years</time_frame>
    <description>The recognition of volatile organic compound profiles in exhaled air by an electronic nose device can discriminate the inflammatory phenotype of patients with persistent asthma.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Persistent Asthma</condition>
  <arm_group>
    <arm_group_label>enose</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electronic nose</intervention_name>
    <description>Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L &quot;Tedlar bag&quot;. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile.</description>
    <arm_group_label>enose</arm_group_label>
    <other_name>Cyranose 320®; Smith Detections, Pasadena, CA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults with persistent asthma, defined as per the Global INitiative for Asthma Management
        (GINA) criteria, and specifically with positive bronchodilator test, or a daily peak
        expiratory flow (PEF) variability greater than 20%, or a positive methacholine challenge
        test documented in case history. Subjects were consecutively enrolled from the outpatient
        visits of a specialized Asthma Unit located in a tertiary University Hospital.

        Exclusion Criteria:

        Subjects were excluded if they had a respiratory tract infection or asthma exacerbation
        within 30 days prior to inclusion or were receiving oral steroids or immunosuppressive
        treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Plaza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau. Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau). Universitat Autònoma de Barcelona, Department of Medicine. Barcelona Respiratory Network (BRN). Barcelona, Spain.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vicente Plaza</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://Www.ginasthma.org/.</url>
    <description>GINA. Global strategy for asthma management and prevention, global initiative for asthma (GINA)</description>
  </link>
  <reference>
    <citation>Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1076-82. doi: 10.1164/rccm.200906-0939OC. Epub 2009 Aug 27.</citation>
    <PMID>19713445</PMID>
  </reference>
  <reference>
    <citation>Dragonieri S, Annema JT, Schot R, van der Schee MP, Spanevello A, Carratú P, Resta O, Rabe KF, Sterk PJ. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer. 2009 May;64(2):166-70. doi: 10.1016/j.lungcan.2008.08.008. Epub 2008 Oct 1.</citation>
    <PMID>18834643</PMID>
  </reference>
  <reference>
    <citation>Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012 Mar;67(3):199-208. doi: 10.1136/thx.2010.135574. Epub 2010 Oct 11. Review.</citation>
    <PMID>20937641</PMID>
  </reference>
  <reference>
    <citation>Executive Committee GEMA 2009. GEMA 2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol. 2010;20 Suppl 1:1-59.</citation>
    <PMID>21413563</PMID>
  </reference>
  <reference>
    <citation>Montuschi P, Santonico M, Mondino C, Pennazza G, Mantini G, Martinelli E, Capuano R, Ciabattoni G, Paolesse R, Di Natale C, Barnes PJ, D'Amico A. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest. 2010 Apr;137(4):790-6. doi: 10.1378/chest.09-1836. Epub 2010 Jan 15.</citation>
    <PMID>20081096</PMID>
  </reference>
  <reference>
    <citation>Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax. 2011 Sep;66(9):804-9. doi: 10.1136/thx.2010.156695. Epub 2011 Jul 11.</citation>
    <PMID>21749985</PMID>
  </reference>
  <reference>
    <citation>Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012 May 4;18(5):716-25. doi: 10.1038/nm.2678. Review.</citation>
    <PMID>22561835</PMID>
  </reference>
  <reference>
    <citation>Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12. Erratum in: Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text.</citation>
    <PMID>24337046</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</investigator_affiliation>
    <investigator_full_name>Astrid Crespo</investigator_full_name>
    <investigator_title>Inflammatory Asthma Phenotypes Discrimination by an Electronic Nose Breath Analyzer</investigator_title>
  </responsible_party>
  <keyword>asthma; inflammation; electronic nose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

